A recent study demonstrated that in a MASH mouse model, an SGLT2 inhibitor increased hepatic autophagic flux via AMPK–TFEB (transcription factor EB) activation, while simultaneously decreasing steatosis, inflammation, and fibrosis (Figure 2). Here, TFEB is linked to steatosis.